Table 1 Demographic, laboratory, physiologic, and radiologic data and treatments in patients with AE-SAID-ILD
|  | AE-SAID-ILD (n = 25) |
|---|---|
Age, year | 72 (55, 85) |
Sex, male / female | 17 / 8 |
Smoking, never / ex / current | 6 / 18 / 1 |
Pack-year of smoking | 27.5 (0, 144) |
Surgical lung biopsy, +/- | 6 / 17 |
Period from ILD diagnosis to first AE, mo | 74 (0, 226) |
Period from SAID diagnosis to first AE, mo | 64 (0, 365) |
ILD preceding SAID, +/-  | 7 / 18 |
Observation period, day | 60 (0, 228) |
Data before AE a | |
 FVC, % pred | 79.1 (49, 111) |
 DLCO, % pred | 62.1 (39.3, 82.0) |
 PaO2 at rest, Torr | 77.3 (61.3, 86.4) |
 UIP pattern on HRCT, +/- / unknown | 12 / 10 / 3 |
 Extent scores on HRCT (full score: 25) | 12 (2, 20) |
 JRS severity grade, I / II / III / IV / unknown | 6 / 0 / 3 / 1 / 15 |
 The GAP staging system, I / II / III / unknown | 8 / 3 / 0 / 14 |
 Preceding immunosuppressive treatments, +/-  | 20 / 5 |
 Preceding antifibrotic treatments, +/-  | 1 / 24 |
 Preceding oxygen therapy, +/-  | 4 / 21 |
Data at AE | |
 Peripheral blood WBC, × 103/μL | 11.6 (7.4, 22.8) |
 Peripheral blood Neut, × 103/μL | 10.7 (6.3, 19.4) |
 Serum CRP, mg/dL | 10.2 (1.5, 31.8) |
 Serum LDH, IU/L | 405 (202, 815) |
 Serum KL-6, U/mL | 1463 (340, 4341) |
 Serum SP-D, ng/mL | 329 (74, 2950) |
 P/F ratio | 180 (57, 328) |
 Extent scores on HRCT at AE (full score: 25) | 18.5 (10, 25) |
 HRCT pattern at AE, peripheral / multifocal / diffuse / unknown | 2 / 3 / 19 / 1 |
 Administration of steroid pulse therapy b, +/-  | 25 / 0 |
 Duration from admission to starting treatments for AE, days | 2 (0, 13) |
 Administration of Immunosuppressants, +/-  | 13 / 12 |
 Treatment with PMX-DHP, +/-  | 8 / 17 |
 Duration from admission to starting PMX-DHP, days | 2 (0, 16) |
 Intubation, +/-  | 6 / 19 |